LT3443009T - Anti-tim-3 antikūnai ir kompozicijos - Google Patents

Anti-tim-3 antikūnai ir kompozicijos

Info

Publication number: LT3443009T
Authority: LT; Lithuania
Prior art keywords: tim; antibodies; compositions
Prior art date: 2016-04-12

Application number

LTEPPCT/EP2017/058696T

Other languages

English (en)

Inventor

Trine Lindsted

Torben Gjetting

Gunther Roland GALLER

Monika GAD

Michael Monrad Grandal

Klaus Koefoed

Michael Kragh

Ivan David Horak

Thomas Bouquin

Mikkel Wandahl Pedersen

Original Assignee

Symphogen A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-04-12

Filing date

2017-04-11

Publication date

2021-12-27

2017-04-11 Application filed by Symphogen A/S filed Critical Symphogen A/S

2021-12-27 Publication of LT3443009T publication Critical patent/LT3443009T/lt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)

LTEPPCT/EP2017/058696T 2016-04-12 2017-04-11 Anti-tim-3 antikūnai ir kompozicijos LT3443009T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662321476P	2016-04-12	2016-04-12
PCT/EP2017/058696 WO2017178493A1 (en)	2016-04-12	2017-04-11	Anti-tim-3 antibodies and compositions

Publications (1)

Publication Number	Publication Date
LT3443009T true LT3443009T (lt)	2021-12-27

Family

ID=58547516

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEPPCT/EP2017/058696T LT3443009T (lt)	2016-04-12	2017-04-11	Anti-tim-3 antikūnai ir kompozicijos

Country Status (35)

Country	Link
US (2)	US11390674B2 (lt)
EP (2)	EP3978531A1 (lt)
JP (2)	JP7123804B2 (lt)
KR (1)	KR102473028B1 (lt)
CN (2)	CN109451741B (lt)
AU (1)	AU2017251250B2 (lt)
CA (1)	CA3020647A1 (lt)
CL (1)	CL2018002878A1 (lt)
CO (1)	CO2018010458A2 (lt)
CY (1)	CY1125440T1 (lt)
DK (1)	DK3443009T3 (lt)
EA (1)	EA039020B1 (lt)
ES (1)	ES2900381T3 (lt)
HR (1)	HRP20211820T1 (lt)
HU (1)	HUE056677T2 (lt)
IL (1)	IL262176B2 (lt)
LT (1)	LT3443009T (lt)
MA (1)	MA44659B1 (lt)
MD (1)	MD3443009T2 (lt)
MX (1)	MX2018012076A (lt)
MY (1)	MY199098A (lt)
NZ (1)	NZ746755A (lt)
PE (1)	PE20181805A1 (lt)
PH (1)	PH12018502112B1 (lt)
PL (1)	PL3443009T3 (lt)
PT (1)	PT3443009T (lt)
RS (1)	RS62736B1 (lt)
SA (1)	SA518400222B1 (lt)
SG (2)	SG11201808724SA (lt)
SI (1)	SI3443009T1 (lt)
TN (1)	TN2018000333A1 (lt)
TW (1)	TWI752950B (lt)
UA (1)	UA126854C2 (lt)
WO (1)	WO2017178493A1 (lt)
ZA (1)	ZA201806429B (lt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE048111T2 (hu)	2015-03-23	2020-05-28	Bayer Pharma AG	Anti-CEACAM6 ellenanyagok és alkalmazásuk
SG11201900026TA (en)	2016-07-14	2019-01-30	Bristol Myers Squibb Co	Antibodies against tim3 and uses thereof
KR102737715B1 (ko)	2017-04-05	2024-12-03	르 라보레또레 쎄르비에르	Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법
SG11202001211TA (en)	2017-08-28	2020-03-30	Bristol Myers Squibb Co	Tim-3 antagonists for the treatment and diagnosis of cancers
JP7358361B2 (ja) *	2018-01-12	2023-10-10	ブリストル－マイヤーズスクイブカンパニー	Ｔｉｍ３に対する抗体およびその使用
EP3768725A4 (en) *	2018-03-20	2021-06-02	Wuxi Biologics Ireland Limited	NEW ANTI-TIM-3 ANTIBODIES
CA3093407A1 (en)	2018-03-23	2019-09-26	Bristol-Myers Squibb Company	Antibodies against mica and/or micb and uses thereof
WO2019196911A1 (en) *	2018-04-12	2019-10-17	Nanjing Leads Biolabs Co., Ltd.	Antibody binding tim-3 and use thereor
CN111886023B (zh) *	2018-04-24	2024-09-27	安源医药科技（上海）有限公司	针对tim-3的抗体及其用途
CN112566936B (zh) *	2018-08-21	2024-07-12	阿尔伯特爱因斯坦医学院	针对人tim-3的单克隆抗体
CN111253485A (zh) *	2018-11-30	2020-06-09	上海开拓者生物医药有限公司	抗人tim-3单克隆抗体及其应用
EP3897844B1 (en)	2018-12-19	2023-11-15	Deutsches Krebsforschungszentrum	Pharmaceutical combination of anti ceacam6 and tim3 antibodies
WO2020243568A1 (en)	2019-05-30	2020-12-03	Bristol-Myers Squibb Company	Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
CN114174538A (zh)	2019-05-30	2022-03-11	百时美施贵宝公司	适合于免疫肿瘤学疗法的多肿瘤基因特征
CN114174537A (zh)	2019-05-30	2022-03-11	百时美施贵宝公司	细胞定位特征和组合疗法
JP2022548627A (ja) *	2019-09-16	2022-11-21	ノバルティスアーゲー	骨髄線維症の治療のための、高親和性のリガンドを遮断するヒト化抗ｔ細胞免疫グロブリンドメイン及びムチンドメイン３（ｔｉｍ－３）ｉｇｇ４抗体の使用
KR102572804B1 (ko) *	2020-02-25	2023-08-31	국립암센터	CD11b+ 세포에서 TIM-3의 발현 수준을 측정하는 암 진단 또는 예후 예측을 위한 정보제공 방법
BR112022015977A2 (pt) *	2020-02-28	2022-10-11	Symphogen As	Anticorpos anti-axl e composições
CN113214396B (zh) *	2020-07-31	2022-04-19	北京市神经外科研究所	抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途
CN114057874B (zh) *	2020-07-31	2023-05-05	北京市神经外科研究所	抗cd44的单链抗体及其在制备治疗肿瘤的药物中的用途
CA3190660A1 (en)	2020-08-31	2022-03-03	George C. Lee	Cell localization signature and immunotherapy
WO2022120179A1 (en)	2020-12-03	2022-06-09	Bristol-Myers Squibb Company	Multi-tumor gene signatures and uses thereof
SMT202500208T1 (it)	2020-12-28	2025-07-22	Bristol Myers Squibb Co	Composizioni anticorpali e metodi per il loro uso
JP2024501029A (ja)	2020-12-28	2024-01-10	ブリストル－マイヤーズスクイブカンパニー	Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
EP4314068A1 (en)	2021-04-02	2024-02-07	The Regents Of The University Of California	Antibodies against cleaved cdcp1 and uses thereof
JP2024516616A (ja)	2021-04-23	2024-04-16	スゾウネオロジクスバイオサイエンスシーオー．，エルティーディー．	Ｔｉｍ－３を標的とする抗体及びその使用
TW202313683A (zh) *	2021-06-01	2023-04-01	丹麥商賽門弗鎮公司	抗nkg2a抗體及組合物
EP4372006A4 (en) *	2021-07-16	2025-10-08	Brightpath Biotherapeutics Co Ltd	ANTIBODY OR ANTIBODY DERIVATIVE TO TIM-3 ANTIGEN, AND USE THEREOF
WO2023031366A1 (en)	2021-09-02	2023-03-09	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Anti-cecam6 antibodies with reduced side-effects
EP4396227B1 (en)	2021-09-03	2025-07-09	OncoOne Research & Development GmbH	Improved fc silenced anti-oxmif antibodies with reduced aggregation potential and reduced hydrophobicity
JP2025509749A (ja)	2022-03-18	2025-04-11	ブリストル－マイヤーズスクイブカンパニー	ポリペプチドの単離方法
CN119562830A (zh)	2022-06-02	2025-03-04	百时美施贵宝公司	抗体组合物及其使用方法
GB2644480A (en)	2023-04-24	2026-04-15	King Abdullah Univ Of Science Of Technology	Compositions, systems and methods for multiplex detection of target biomarkers in a sample
WO2025038763A1 (en)	2023-08-15	2025-02-20	Bristol-Myers Squibb Company	Ceramic hydroxyapatite chromatography flow through method
WO2025145207A1 (en)	2023-12-29	2025-07-03	Bristol-Myers Squibb Company	Combination therapy of kras inhibitor and treg-depleting agent
CN118373913B (zh) *	2024-05-08	2024-11-01	上海百英生物科技股份有限公司	一种抗人Tim-3单克隆抗体及其制备方法
CN118165111B (zh) *	2024-05-15	2024-08-13	中国人民解放军军事科学院军事医学研究院	针对Tim-3的抗体

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
US4740461A (en)	1983-12-27	1988-04-26	Genetics Institute, Inc.	Vectors and methods for transformation of eucaryotic cells
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
DE3668186D1 (de)	1985-04-01	1990-02-15	Celltech Ltd	Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US4959455A (en)	1986-07-14	1990-09-25	Genetics Institute, Inc.	Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en)	1986-11-14	1990-03-27	Genetics Institute, Inc.	Eucaryotic expression system
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
EP1105427A2 (en)	1998-08-17	2001-06-13	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives
US6517529B1 (en)	1999-11-24	2003-02-11	Radius International Limited Partnership	Hemodialysis catheter
US20110059106A1 (en)	2008-01-29	2011-03-10	Brigham And Women's Hospital, Inc.	Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
WO2010084999A1 (en)	2009-01-26	2010-07-29	Protegene, Inc.	Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases
ES2571235T3 (es)	2009-04-10	2016-05-24	Kyowa Hakko Kirin Co Ltd	Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
WO2011155607A1 (ja)	2010-06-11	2011-12-15	協和発酵キリン株式会社	抗ｔｉｍ－３抗体
CA2802344C (en)	2010-06-18	2023-06-13	The Brigham And Women's Hospital, Inc.	Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
WO2013006490A2 (en) *	2011-07-01	2013-01-10	Cellerant Therapeutics, Inc.	Antibodies that specifically bind to tim3
SG11201505960VA (en)	2013-02-01	2015-08-28	Santa Maria Biotherapeutics Inc	Administration of an anti-activin-a compound to a subject
EP3757130A1 (en)	2013-09-26	2020-12-30	Costim Pharmaceuticals Inc.	Methods for treating hematologic cancers
CN103936853B (zh)	2014-01-26	2016-08-17	中国人民解放军军事医学科学院基础医学研究所	一种检测tim-3试剂盒及其使用方法
AU2015210750B2 (en)	2014-01-31	2020-08-20	Children's Medical Center Corporation	Antibody molecules to TIM-3 and uses thereof
ES3040431T3 (en)	2014-03-12	2025-10-31	Yeda Res & Dev	Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
CA2946606C (en)	2014-05-13	2023-06-06	Bavarian Nordic A/S	Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist of tim-3
US20160200815A1 (en)	2015-01-05	2016-07-14	Jounce Therapeutics, Inc.	Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
CN107922484A (zh)	2015-03-06	2018-04-17	索伦托治疗有限公司	结合tim3的抗体治疗剂
WO2017019897A1 (en)	2015-07-29	2017-02-02	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
US11014983B2 (en)	2015-08-20	2021-05-25	Sutro Biopharma, Inc.	Anti-Tim-3 antibodies, compositions comprising anti-Tim-3 antibodies and methods of making and using anti-Tim-3 antibodies
DK3356411T3 (da)	2015-10-02	2021-09-06	Hoffmann La Roche	Bispecifikke antistoffer, der er specifikke for PD1 og TIM3
SG11201900026TA (en)	2016-07-14	2019-01-30	Bristol Myers Squibb Co	Antibodies against tim3 and uses thereof
JOP20190013A1 (ar)	2016-08-25	2019-01-31	Lilly Co Eli	أجسام مضادة لـ (تي آي ام -3)
JOP20190133A1 (ar)	2016-12-08	2019-06-02	Innovent Biologics Suzhou Co Ltd	أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
KR102737715B1 (ko)	2017-04-05	2024-12-03	르 라보레또레 쎄르비에르	Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법
JOP20190222A1 (ar)	2017-04-11	2019-09-24	Zymeworks Inc	الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3

2017
- 2017-04-11 RS RS20211517A patent/RS62736B1/sr unknown
- 2017-04-11 AU AU2017251250A patent/AU2017251250B2/en active Active
- 2017-04-11 KR KR1020187032586A patent/KR102473028B1/ko active Active
- 2017-04-11 ES ES17717393T patent/ES2900381T3/es active Active
- 2017-04-11 MX MX2018012076A patent/MX2018012076A/es unknown
- 2017-04-11 IL IL262176A patent/IL262176B2/en unknown
- 2017-04-11 UA UAA201811058A patent/UA126854C2/uk unknown
- 2017-04-11 TW TW106112034A patent/TWI752950B/zh active
- 2017-04-11 NZ NZ746755A patent/NZ746755A/en unknown
- 2017-04-11 US US16/093,024 patent/US11390674B2/en active Active
- 2017-04-11 CN CN201780023412.9A patent/CN109451741B/zh active Active
- 2017-04-11 TN TNP/2018/000333A patent/TN2018000333A1/en unknown
- 2017-04-11 LT LTEPPCT/EP2017/058696T patent/LT3443009T/lt unknown
- 2017-04-11 PL PL17717393T patent/PL3443009T3/pl unknown
- 2017-04-11 PH PH1/2018/502112A patent/PH12018502112B1/en unknown
- 2017-04-11 HR HRP20211820TT patent/HRP20211820T1/hr unknown
- 2017-04-11 CA CA3020647A patent/CA3020647A1/en active Pending
- 2017-04-11 MY MYPI2018703580A patent/MY199098A/en unknown
- 2017-04-11 PT PT177173937T patent/PT3443009T/pt unknown
- 2017-04-11 CN CN202310660864.5A patent/CN116693685A/zh active Pending
- 2017-04-11 SG SG11201808724SA patent/SG11201808724SA/en unknown
- 2017-04-11 JP JP2018553410A patent/JP7123804B2/ja active Active
- 2017-04-11 EA EA201892294A patent/EA039020B1/ru unknown
- 2017-04-11 HU HUE17717393A patent/HUE056677T2/hu unknown
- 2017-04-11 SI SI201731008T patent/SI3443009T1/sl unknown
- 2017-04-11 PE PE2018001979A patent/PE20181805A1/es unknown
- 2017-04-11 DK DK17717393.7T patent/DK3443009T3/da active
- 2017-04-11 SG SG10201912937SA patent/SG10201912937SA/en unknown
- 2017-04-11 MD MDE20190216T patent/MD3443009T2/ro unknown
- 2017-04-11 EP EP21194637.1A patent/EP3978531A1/en active Pending
- 2017-04-11 EP EP17717393.7A patent/EP3443009B1/en active Active
- 2017-04-11 MA MA44659A patent/MA44659B1/fr unknown
- 2017-04-11 WO PCT/EP2017/058696 patent/WO2017178493A1/en not_active Ceased
2018
- 2018-09-27 ZA ZA2018/06429A patent/ZA201806429B/en unknown
- 2018-09-28 CO CONC2018/0010458A patent/CO2018010458A2/es unknown
- 2018-10-09 CL CL2018002878A patent/CL2018002878A1/es unknown
- 2018-10-11 SA SA518400222A patent/SA518400222B1/ar unknown
2021
- 2021-12-08 CY CY20211101076T patent/CY1125440T1/el unknown
2022
- 2022-05-11 US US17/741,967 patent/US12577302B2/en active Active
- 2022-08-10 JP JP2022128330A patent/JP2022172142A/ja active Pending

Also Published As

Publication number	Publication date
MX2018012076A (es)	2019-02-20
HRP20211820T1 (hr)	2022-03-04
EP3978531A1 (en)	2022-04-06
BR112018070919A2 (pt)	2019-01-29
CN116693685A (zh)	2023-09-05
SG10201912937SA (en)	2020-02-27
UA126854C2 (uk)	2023-02-15
EA201892294A1 (ru)	2019-04-30
JP2022172142A (ja)	2022-11-15
IL262176B (en)	2022-11-01
MA44659B1 (fr)	2021-12-31
EP3443009B1 (en)	2021-09-08
CY1125440T1 (el)	2023-03-24
SG11201808724SA (en)	2018-11-29
TW201736397A (zh)	2017-10-16
US20190276531A1 (en)	2019-09-12
NZ746755A (en)	2025-11-28
ZA201806429B (en)	2023-02-22
HUE056677T2 (hu)	2022-02-28
PH12018502112A1 (en)	2019-09-23
PL3443009T3 (pl)	2022-01-31
CO2018010458A2 (es)	2018-10-10
DK3443009T3 (da)	2021-12-13
ES2900381T3 (es)	2022-03-16
MD3443009T2 (ro)	2022-02-28
RS62736B1 (sr)	2022-01-31
US20230105714A1 (en)	2023-04-06
PE20181805A1 (es)	2018-11-19
PT3443009T (pt)	2021-12-10
SA518400222B1 (ar)	2022-03-14
IL262176A (en)	2018-11-29
KR20180133482A (ko)	2018-12-14
US11390674B2 (en)	2022-07-19
CA3020647A1 (en)	2017-10-19
EP3443009A1 (en)	2019-02-20
MA44659A (fr)	2021-04-14
EA039020B1 (ru)	2021-11-23
AU2017251250A1 (en)	2018-10-18
TWI752950B (zh)	2022-01-21
PH12018502112B1 (en)	2024-03-27
US12577302B2 (en)	2026-03-17
WO2017178493A1 (en)	2017-10-19
MY199098A (en)	2023-10-12
CN109451741A (zh)	2019-03-08
JP2019519199A (ja)	2019-07-11
CL2018002878A1 (es)	2019-04-26
SI3443009T1 (sl)	2022-04-29
KR102473028B1 (ko)	2022-11-30
JP7123804B2 (ja)	2022-08-23
IL262176B2 (en)	2023-03-01
TN2018000333A1 (en)	2020-01-16
CN109451741B (zh)	2023-07-28
AU2017251250B2 (en)	2024-03-21

Publication	Publication Date	Title
IL283965A (en)	2021-07-29	Antibodies against cd73 and uses thereof
PT3443009T (pt)	2021-12-10	Anticorpos anti-tim-3 e composições
IL265844A (en)	2019-06-30	Anti-lag-3 antibodies and preparations
LT3280441T (lt)	2021-11-25	Anti-sortilino antikūnai ir jų naudojimo būdai
KR102162129B9 (ko)	2023-02-08	항-갈렉틴-9 항체 및 이의 용도
LT3558390T (lt)	2024-11-11	Amanitino ir antikūnų konjugatai
LT3303394T (lt)	2020-10-12	Anti-ctla-4 antikūnai ir jų naudojimo būdai
LT3215532T (lt)	2020-01-10	Anti-tim3 antikūnai ir jų naudojimo būdai
LT3347379T (lt)	2020-05-11	Anti-tigit antikūnai, anti-pvrig antikūnai ir jų kombinacijos
LT3827845T (lt)	2022-06-10	Poodinės anti-cd38 antikūnų kompozicijos ir jų naudojimas
DK3541841T3 (da)	2024-10-21	Anti-PD-1-antistoffer og sammensætninger
LT3317284T (lt)	2020-01-27	Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai
DK3368572T3 (da)	2022-08-08	Anti-pd-1-antistoffer og -sammensætninger
EP3426686C0 (en)	2025-10-08	Humanized Anti-PACAP Antibodies and Their Uses
LT3333191T (lt)	2020-12-10	Anti-c10orf54 antikūnai ir jų panaudojimas
LT3191135T (lt)	2020-11-25	Anti-her2 antikūnai ir imunokonjugatai
LT3148579T (lt)	2021-05-25	Anti-gitr antikūnai ir jų panaudojimo būdai
LT3126388T (lt)	2019-08-26	Antikūnai prieš egfrviii ir jų panaudojimo būdai
LT3250610T (lt)	2023-09-25	Fcrn antikūnai ir jų panaudojimo būdai
LT3653221T (lt)	2022-11-10	Anti-pvrig antikūnai ir naudojimo būdai
LT3274370T (lt)	2020-02-10	Antikūnai prieš ceacam6 ir jų panaudojimas
LT3491025T (lt)	2023-11-27	Fcrn antikūnai ir jų panaudojimo būdai
IL260688A (en)	2018-10-31	Antibody preparations for ror2 and methods related thereto
DK3484446T3 (da)	2024-11-04	Antistofsammensætninger
LT3102555T (lt)	2021-06-25	Junginių kompozicijos ir jų panaudojimas